Sanofi CFO on 1Q Profits, Growth

The transcript discusses Sanofi's growth drivers, including Dupixent's new indication for COPD and other product launches like Altuvio and Bay Fortress. It covers regulatory approval timelines, market strategies, and sales estimates. The future of Sanofi's immunology pipeline is highlighted, along with addressing legal risks related to Zantac. The role of AI in pharmaceutical research is also explored, emphasizing its impact on identifying drug indications and improving patient outcomes.

What are the expectations regarding the regulatory approval timeline for Dupixent?

How does the company view the risks associated with Zantac?

In what ways is AI expected to disrupt the pharmaceutical industry?